Bio-Techne makes $10M collateral investment in CyVek Techne Company.

Bio-Techne makes $10M collateral investment in CyVek Techne Company , d/b/a Bio-Techne, announced today that it all has made a $10 million equity expenditure in CyVek, Inc. , with a committed action to obtain CyVek if certain potential milestones are fulfilled priligy vendu . CyVek is rolling out a transformative immunoassay technology, CyPlexTM, which integrates an innovatively designed microfluidic cartridge with a state-of-the-artwork analyzer to provide the innovative and efficient bench best immunoassay system. CyPlex'sTM capability to offer sample to answer test outcomes precisely and quickly in a sealed disposable gadget makes it an extremely attractive system for clinical applications.